Brain Cancer Research

Brain cancer research explores novel drug delivery methods, immunotherapy approaches, and precision medicine for glioblastoma and other brain tumors.

Our Brain Cancer Analysis

• August 20, 2026JAMA Oncology

  Meningioma Diagnoses Nearly Doubled in Denmark Over 14 Years — But Most Surveillance Scans Never Led to Treatment

  A nationwide Danish registry study of 8,134 patients found that age- and sex-standardized meningioma incidence nearly doubled between 2010 and 2023, rising from 6.4 to 12.6 cases per 100,000 person-years, while the proportion of diagnosed patients who ultimately received surgery fell from 43.9% to 23.4%.

• August 20, 2026JAMA Oncology

  Industry Now Outpaces Federal Cancer Trial Sponsorship Nearly 5 to 1 — And the Gap Is Widening

  A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.

• August 10, 2026Journal of Clinical OncologyNRG Oncology RTOG 0539 (NCT00895622)

  10-Year Data Validate Risk-Adapted Meningioma Strategy: Observation, Then Selective Radiotherapy

  Long-term follow-up (median exceeding 10 years) of NRG Oncology RTOG 0539 validates a risk-adapted meningioma strategy: observation after gross total or subtotal resection for low-risk (WHO grade 1) disease, and radiotherapy for intermediate- and high-risk disease.

• July 10, 2026Nature MedicineABTC 1501 (NCT02658981)

  Phase 1 Trial: Anti-LAG-3 Plus Anti-PD-1 Shows Acceptable Safety in Recurrent Glioblastoma

  Open-label, multicenter phase 1 trial (Adult Brain Tumor Consortium, ABTC 1501) of the anti-LAG-3 antibody relatlimab, alone or combined with the anti-PD-1 antibody nivolumab, in 46 patients with first-time recurrent glioblastoma (GBM)